---
title: Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
nct_id: NCT02595424
overall_status: ACTIVE_NOT_RECRUITING
phase: PHASE2
sponsor: ECOG-ACRIN Cancer Research Group
study_type: INTERVENTIONAL
primary_condition: Gastric Neuroendocrine Carcinoma
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02595424.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02595424"
ct_last_update_post_date: 2026-05-01
last_seen_at: "2026-05-12T06:11:49.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

**Official Title:** Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

**NCT ID:** [NCT02595424](https://clinicaltrials.gov/study/NCT02595424)

## Key Facts

- **Status:** ACTIVE_NOT_RECRUITING
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 67
- **Lead Sponsor:** ECOG-ACRIN Cancer Research Group
- **Collaborators:** National Cancer Institute (NCI)
- **Conditions:** Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
- **Start Date:** 2015-11-06
- **Completion Date:** 2029-01-01
- **CT.gov Last Update:** 2026-05-01

## Brief Summary

This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, capecitabine, cisplatin, carboplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Certain types of neuroendocrine carcinomas may respond better to treatments other than the current standard treatment of cisplatin and etoposide. It is not yet known whether temozolomide and capecitabine may work better than cisplatin or carboplatin and etoposide in treating patients with this type of neuroendocrine carcinoma, called non-small cell neuroendocrine carcinoma.

## Detailed Description

PRIMARY OBJECTIVES:

I. To assess the progression free survival (PFS) of platinum (cisplatin or carboplatin) and etoposide versus the PFS of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.

SECONDARY OBJECTIVES:

I. To assess the response rate (RR) of platinum (cisplatin or carboplatin) and etoposide versus the RR of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.

II. To assess the overall survival (OS) of platinum (cisplatin or carboplatin) and etoposide versus the OS of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.

III. To evaluate the toxicities associated with the combination of temozolomide and capecitabine and the combination of platinum (cisplatin or carboplatin) and etoposide, respectively, in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.

TERTIARY OBJECTIVES:

I. To assess the impact of each treatment regimen on PFS, RR and OS based on marker of proliferation Ki-67 index in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas. (Laboratory) II. To assess the prognostic significance of well differentiated versus poorly differentiated non-small cell gastroenteropancreatic neuroendocrine tumors in relationship to survival and response to treatment. (Laboratory) III. To assess the agreement in Ki-67 status between that reported by institutional pathologist and that reported by central pathology review. (Laboratory)

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14 and temozolomide PO once daily (QD) on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive cisplatin intravenously (IV) on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients must have a locally advanced and unresectable or metastatic gastroenteropancreatic neuroendocrine carcinoma that is either known or suspected to be of gastrointestinal (GI) origin; primary tumors arising from the lung, gynecologic organs or prostate are not permitted
* Patients must have pathologically/histologically confirmed tumor of non-small cell histology
* Patients must have a Ki-67 proliferative index of 20-100% OR at least 10 mitotic figures per 10 high powered fields
* Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained within 4 weeks prior to randomization and must be acquired by multiphasic computed tomography (CT) or contrast magnetic resonance imaging (MRI)

  * NOTE: positron emission tomography (PET)-CT scans are allowed provided the CT portion of the exam is equivalent to a diagnostic CT scan and includes both oral and IV contrast
* Any prior surgeries must have been completed at least 4 weeks prior to randomization
* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Patients may not be receiving any other investigational agents while on study treatment
* Patients may not be receiving Coumadin while on treatment; other anticoagulants are allowed
* Leukocytes \>= 3,000/mm\^3
* Absolute neutrophil count \>= 1,500/mm\^3
* Hemoglobin \>= 9 g/dL
* Platelets \>= 100,000/mm\^3
* Total bilirubin =\< institutional upper limit of normal (ULN) or =\< 1.5 X institutional ULN (if the patient has liver metastases)
* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional ULN or (=\< 5 X institutional ULN if the patient has liver metastases)
* Serum creatinine =\< 1.5 X institutional ULN and creatinine clearance \>= 60 ml/min

  * NOTE: creatinine clearance must be calculated using the Cockcroft-Gault equation
* Patients must have a life expectancy of \>= 12 weeks as determined clinically by the treating physician
* Patients with impaired decision-making capacity may participate in the study if a legal authorized representative is available to consent
* Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study
* Patients must be able to swallow pills
* Patients must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for the treatment and the protocol

Exclusion Criteria:

* Patients may not have had any prior systemic treatment for this malignancy (for example chemotherapy or somatostatin analogues); prior palliative radiation is permitted but radiated lesions may not be used for measurement
* Patients may not have received any of the protocol agents within 5 years prior to randomization
* Patients with brain metastases (either remote or current) or presence of carcinomatous meningitis are not eligible
* Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency will be excluded
* Patients must NOT have active or uncontrolled infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia or a serious psychiatric illness/social situation that would limit compliance with study requirements
* Patients must NOT have a history of allergic reactions attributed to compounds of similar chemical or biochemical composition to cisplatin, carboplatin, etoposide, temozolomide or capecitabine
* Patients must NOT have absorption issues that would limit the ability to absorb study agents
* Patients with a history of the following within =\< 12 months of study entry are not eligible:

  * Arterial thromboembolic events
  * Unstable angina
  * Myocardial Infarction
* Patients with symptomatic peripheral vascular disease are not eligible
* Patients must NOT have previous or concurrent malignancy; exceptions are made for patients who meet any of the following conditions:

  * Non-melanoma skin cancer, in situ cervical cancer, superficial bladder cancer, or breast cancer in situ OR
  * Prior malignancy completely excised or removed and patient has been continuously disease free for \> 5 years OR
  * Prior malignancy cured by non-surgical modalities and patient has been continuously disease free for \> 5 years
* Women must not be pregnant or breast-feeding

  * All females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy
  * A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
* Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible
```

## Arms

- **Arm A (capecitabine, temozolomide)** (EXPERIMENTAL) — Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- **Arm B (cisplatin, carboplatin, etoposide)** (ACTIVE_COMPARATOR) — Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

## Interventions

- **Capecitabine** (DRUG) — Given PO
- **Carboplatin** (DRUG) — Given IV
- **Cisplatin** (DRUG) — Given IV
- **Etoposide** (DRUG) — Given IV
- **Laboratory Biomarker Analysis** (OTHER) — Correlative studies
- **Temozolomide** (DRUG) — Given PO

## Primary Outcomes

- **Progression-free Survival (PFS)** _(time frame: assessed at baseline, every 8 weeks until treatment completion, then every 3 months within 2 years and every 6 months within 3-5 years from randomization until disease progression, up to 5 years from study registration)_ — PFS is defined as the time from randomization to documented progression or death without progression. PFS is censored at the date of last disease evaluation. The study was closed for futility in 2021 after the 2021 Spring DSMC meeting, which found that the boundary for futility had been met (ie, temozolomide and capecitabine did not appear to be superior to platinum and etoposide chemotherapy). As the interim analysis finding led to the conclusion of the study, no PFS stratified logrank test was conducted with the data extracted on April 23rd, 2025 for the final analysis, that was presented here.

## Secondary Outcomes

- **Overall Survival (OS)** _(time frame: assessed at baseline, then every 3 months within 2 years from randomization, and every 6 months if patient is 3-5 years from randomization, up to 5 years from randomization)_
- **Objective Response Rate (ORR)** _(time frame: assessed at baseline, every 8 weeks until treatment completion, then every 3 months within 2 years and every 6 months within 3-5 years, up to 5 years from registration; the best response among all assessments was considered as objective response)_

## Locations (673)

- Kingman Regional Medical Center, Kingman, Arizona, United States
- Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
- Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
- CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
- Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States
- PCR Oncology, Arroyo Grande, California, United States
- Sutter Auburn Faith Hospital, Auburn, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Mills-Peninsula Medical Center, Burlingame, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States
- Eden Hospital Medical Center, Castro Valley, California, United States
- Sutter Davis Hospital, Davis, California, United States
- Kaiser Permanente Dublin, Dublin, California, United States
- Kaiser Permanente-Fremont, Fremont, California, United States
- Palo Alto Medical Foundation-Fremont, Fremont, California, United States
- Kaiser Permanente-Fresno, Fresno, California, United States
- Los Angeles County-USC Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Memorial Medical Center, Modesto, California, United States
- Kaiser Permanente-Modesto, Modesto, California, United States
- Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
- USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
- Sutter Cancer Research Consortium, Novato, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- Palo Alto Medical Foundation Health Care, Palo Alto, California, United States
- Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
- Keck Medical Center of USC Pasadena, Pasadena, California, United States
- Eisenhower Medical Center, Rancho Mirage, California, United States
- Kaiser Permanente-Redwood City, Redwood City, California, United States
- Kaiser Permanente-Richmond, Richmond, California, United States
- Kaiser Permanente-Roseville, Roseville, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States
- Sutter Roseville Medical Center, Roseville, California, United States
- Kaiser Permanente Downtown Commons, Sacramento, California, United States
- Sutter Medical Center Sacramento, Sacramento, California, United States
- Kaiser Permanente-South Sacramento, Sacramento, California, United States
- Kaiser Permanente - Sacramento, Sacramento, California, United States
- California Pacific Medical Center-Pacific Campus, San Francisco, California, United States
- Kaiser Permanente-San Francisco, San Francisco, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States
- Kaiser Permanente San Leandro, San Leandro, California, United States
- Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California, United States
- Kaiser Permanente-San Rafael, San Rafael, California, United States
- Kaiser San Rafael-Gallinas, San Rafael, California, United States
- Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States
- Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States
- Mission Hope Medical Oncology - Santa Maria, Santa Maria, California, United States
- Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States
- Sutter Pacific Medical Foundation, Santa Rosa, California, United States
- Kaiser Permanente-South San Francisco, South San Francisco, California, United States
- Kaiser Permanente-Stockton, Stockton, California, United States
- Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States
- Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States
- Kaiser Permanente-Vallejo, Vallejo, California, United States
- Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States
- Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States
- University of Colorado Hospital, Aurora, Colorado, United States
- Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States
- Porter Adventist Hospital, Denver, Colorado, United States
- Mercy Medical Center, Durango, Colorado, United States
- Southwest Oncology PC, Durango, Colorado, United States
- Mountain Blue Cancer Care Center, Golden, Colorado, United States
- Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States
- Saint Anthony Hospital, Lakewood, Colorado, United States
- Littleton Adventist Hospital, Littleton, Colorado, United States
- Longmont United Hospital, Longmont, Colorado, United States
- Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States
- Parker Adventist Hospital, Parker, Colorado, United States
- Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States
- Saint Mary Corwin Medical Center, Pueblo, Colorado, United States
- Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States
- Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States
- Beebe South Coastal Health Campus, Frankford, Delaware, United States
- Beebe Medical Center, Lewes, Delaware, United States
- Christiana Gynecologic Oncology LLC, Newark, Delaware, United States
- Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States
- Helen F Graham Cancer Center, Newark, Delaware, United States
- Medical Oncology Hematology Consultants PA, Newark, Delaware, United States
- Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
- Beebe Health Campus, Rehoboth Beach, Delaware, United States
- TidalHealth Nanticoke / Allen Cancer Center, Seaford, Delaware, United States
- Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States
- MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
- Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- Holy Cross Hospital, Fort Lauderdale, Florida, United States
- Grady Health System, Atlanta, Georgia, United States
- Emory University Hospital Midtown, Atlanta, Georgia, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
- Emory Johns Creek Hospital, Johns Creek, Georgia, United States
- Medical Center of Central Georgia, Macon, Georgia, United States
- Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States
- Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States
- Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States
- Walter Knox Memorial Hospital, Emmett, Idaho, United States
- Idaho Urologic Institute-Meridian, Meridian, Idaho, United States
- Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho, United States
- Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
- Kootenai Cancer Clinic, Sandpoint, Idaho, United States
- Rush - Copley Medical Center, Aurora, Illinois, United States
- Saint Joseph Medical Center, Bloomington, Illinois, United States
- Illinois CancerCare-Bloomington, Bloomington, Illinois, United States
- Loyola Center for Health at Burr Ridge, Burr Ridge, Illinois, United States
- Illinois CancerCare-Canton, Canton, Illinois, United States
- Memorial Hospital of Carbondale, Carbondale, Illinois, United States
- SIH Cancer Institute, Carterville, Illinois, United States
- Illinois CancerCare-Carthage, Carthage, Illinois, United States
- Centralia Oncology Clinic, Centralia, Illinois, United States
- Northwestern University, Chicago, Illinois, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Carle on Vermilion, Danville, Illinois, United States
- Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States
- Illinois CancerCare-Dixon, Dixon, Illinois, United States
- Carle Physician Group-Effingham, Effingham, Illinois, United States
- Crossroads Cancer Center, Effingham, Illinois, United States
- Illinois CancerCare-Eureka, Eureka, Illinois, United States
- Illinois CancerCare-Galesburg, Galesburg, Illinois, United States
- Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States
- Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States
- Loyola Medicine Homer Glen, Homer Glen, Illinois, United States
- Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States
- Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States
- Illinois CancerCare-Macomb, Macomb, Illinois, United States
- Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- Marjorie Weinberg Cancer Center at Loyola-Gottlieb, Melrose Park, Illinois, United States
- Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
- UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
- Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States
- University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
- Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States
- Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States
- Illinois CancerCare-Pekin, Pekin, Illinois, United States
- OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States
- Illinois CancerCare-Peoria, Peoria, Illinois, United States
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States
- Methodist Medical Center of Illinois, Peoria, Illinois, United States
- OSF Saint Francis Medical Center, Peoria, Illinois, United States
- Illinois CancerCare-Peru, Peru, Illinois, United States
- Valley Radiation Oncology, Peru, Illinois, United States
- Illinois CancerCare-Princeton, Princeton, Illinois, United States
- Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
- Southern Illinois University School of Medicine, Springfield, Illinois, United States
- Springfield Clinic, Springfield, Illinois, United States
- Memorial Medical Center, Springfield, Illinois, United States
- Southwest Illinois Health Services LLP, Swansea, Illinois, United States
- Carle Cancer Center, Urbana, Illinois, United States
- The Carle Foundation Hospital, Urbana, Illinois, United States
- Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
- Rush-Copley Healthcare Center, Yorkville, Illinois, United States
- Deaconess Clinic Downtown, Evansville, Indiana, United States
- Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States
- Woodland Cancer Care Center, Michigan City, Indiana, United States
- Chancellor Center for Oncology, Newburgh, Indiana, United States
- Reid Health, Richmond, Indiana, United States
- Mary Greeley Medical Center, Ames, Iowa, United States
- McFarland Clinic PC - Ames, Ames, Iowa, United States
- McFarland Clinic PC-Boone, Boone, Iowa, United States
- Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States
- Mercy Cancer Center-West Lakes, Clive, Iowa, United States
- Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States
- Greater Regional Medical Center, Creston, Iowa, United States
- Mercy Medical Center - Des Moines, Des Moines, Iowa, United States
- Mission Cancer and Blood - Laurel, Des Moines, Iowa, United States
- McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States
- McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States
- McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States
- Siouxland Regional Cancer Center, Sioux City, Iowa, United States
- Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States
- Cancer Center of Kansas - Chanute, Chanute, Kansas, United States
- Coffeyville Regional Medical Center, Coffeyville, Kansas, United States
- Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States
- Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States
- Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States
- Central Care Cancer Center - Garden City, Garden City, Kansas, United States
- Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States
- HaysMed University of Kansas Health System, Hays, Kansas, United States
- Cancer Center of Kansas-Independence, Independence, Kansas, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- Cancer Center of Kansas-Kingman, Kingman, Kansas, United States
- Lawrence Memorial Hospital, Lawrence, Kansas, United States
- Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States
- Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States
- Cancer Center of Kansas-Liberal, Liberal, Kansas, United States
- Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States
- Cancer Center of Kansas - McPherson, McPherson, Kansas, United States
- Cancer Center of Kansas - Newton, Newton, Kansas, United States
- Olathe Health Cancer Center, Olathe, Kansas, United States
- Menorah Medical Center, Overland Park, Kansas, United States
- _and 473 more_

## Recent Field Changes (last 30 days)

- `locations.aurora cancer care-kenosha south|kenosha|wisconsin|united states` — added _(2026-05-12)_
- `locations.marshfield clinic - ladysmith center|ladysmith|wisconsin|united states` — added _(2026-05-12)_
- `locations.university of wisconsin carbone cancer center|madison|wisconsin|united states` — added _(2026-05-12)_
- `locations.aurora bay area medical group-marinette|marinette|wisconsin|united states` — added _(2026-05-12)_
- `locations.bay area medical center|marinette|wisconsin|united states` — added _(2026-05-12)_
- `locations.marshfield medical center-marshfield|marshfield|wisconsin|united states` — added _(2026-05-12)_
- `locations.aurora cancer care-milwaukee|milwaukee|wisconsin|united states` — added _(2026-05-12)_
- `locations.aurora saint luke's medical center|milwaukee|wisconsin|united states` — added _(2026-05-12)_
- `locations.medical college of wisconsin|milwaukee|wisconsin|united states` — added _(2026-05-12)_
- `locations.aurora sinai medical center|milwaukee|wisconsin|united states` — added _(2026-05-12)_
- `locations.marshfield clinic-minocqua center|minocqua|wisconsin|united states` — added _(2026-05-12)_
- `locations.cancer center of western wisconsin|new richmond|wisconsin|united states` — added _(2026-05-12)_
- `locations.vince lombardi cancer clinic - oshkosh|oshkosh|wisconsin|united states` — added _(2026-05-12)_
- `locations.aurora cancer care-racine|racine|wisconsin|united states` — added _(2026-05-12)_
- `locations.marshfield medical center-rice lake|rice lake|wisconsin|united states` — added _(2026-05-12)_
- `locations.vince lombardi cancer clinic-sheboygan|sheboygan|wisconsin|united states` — added _(2026-05-12)_
- `locations.ascension saint michael's hospital|stevens point|wisconsin|united states` — added _(2026-05-12)_
- `locations.marshfield medical center-river region at stevens point|stevens point|wisconsin|united states` — added _(2026-05-12)_
- `locations.aurora medical center in summit|summit|wisconsin|united states` — added _(2026-05-12)_
- `locations.vince lombardi cancer clinic-two rivers|two rivers|wisconsin|united states` — added _(2026-05-12)_
- `locations.aurora cancer care-waukesha|waukesha|wisconsin|united states` — added _(2026-05-12)_
- `locations.marshfield clinic-wausau center|wausau|wisconsin|united states` — added _(2026-05-12)_
- `locations.aurora cancer care-milwaukee west|wauwatosa|wisconsin|united states` — added _(2026-05-12)_
- `locations.aurora west allis medical center|west allis|wisconsin|united states` — added _(2026-05-12)_
- `locations.marshfield medical center - weston|weston|wisconsin|united states` — added _(2026-05-12)_
- `locations.marshfield clinic - wisconsin rapids center|wisconsin rapids|wisconsin|united states` — added _(2026-05-12)_
- `locations.big horn basin cancer center|cody|wyoming|united states` — added _(2026-05-12)_
- `locations.billings clinic-cody|cody|wyoming|united states` — added _(2026-05-12)_
- `locations.welch cancer center|sheridan|wyoming|united states` — added _(2026-05-12)_
- `locations.ann m wierman md ltd|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.cancer and blood specialists-tenaya|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.comprehensive cancer centers of nevada - northwest|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.genesiscare usa - vegas tenaya|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.healthcare partners medical group oncology/hematology-tenaya|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.las vegas urology - cathedral rock|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.las vegas urology - smoke ranch|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.optumcare cancer care at mountainview|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.urology specialists of nevada - northwest|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.alliance for childhood diseases/cure 4 the kids foundation|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.comprehensive cancer centers of nevada - town center|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.comprehensive cancer centers of nevada-summerlin|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.summerlin hospital medical center|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.las vegas cancer center-medical center|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.comprehensive cancer centers of nevada|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.genesiscare usa - fort apache|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.optumcare cancer care at fort apache|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.healthcare partners medical group oncology/hematology-centennial hills|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.comprehensive cancer centers of nevada - central valley|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.university cancer center|las vegas|nevada|united states` — added _(2026-05-12)_
- `locations.hope cancer care of nevada-pahrump|pahrump|nevada|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02595424.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02595424*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*